Akero Therapeutics, Inc. — Director's Dealing 2021

Jun 3, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Akero Therapeutics, Inc. (AKRO)
CIK: 0001744659
Period of Report: 2021-06-01

Reporting Person: Graham G. Walmsley (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-01	Stock Option (Right to Buy)	$26.32	A	13000	Acquired	2031-05-31	Common Stock (13000)	Direct
2021-06-01	Stock Option (Right to Buy)	$26.32	G	13000	Disposed	2031-05-31	Common Stock (13000)	Direct
2021-06-01	Stock Option (Right to Buy)	$19.97	G	23832	Disposed	2029-11-07	Common Stock (23832)	Direct
2021-06-01	Stock Option (Right to Buy)	$25.2	G	13000	Disposed	2030-05-31	Common Stock (13000)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$26.32	2031-05-31	Common Stock (13000)	13000	Indirect
Stock Option (Right to Buy)	$19.97	2029-11-07	Common Stock (23832)	23832	Indirect
Stock Option (Right to Buy)	$25.2	2030-05-31	Common Stock (13000)	13000	Indirect

Footnotes

F1: This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director.

F2: On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member.

F3: This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019.

F4: On June 1, 2021, the reporting person transferred 23,832 options to an entity of which the reporting person is the sole member.

F5: This option is fully vested.

F6: On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member.